Prostate Health Market Report 2026

Prostate Health Market Overview

• Prostate Health market size has reached to $37.23 billion in 2025 • Expected to grow to $57.39 billion in 2030 at a compound annual growth rate (CAGR) of 9% • Growth Driver: Rising Prostate Cancer Prevalence Drives Demand For Advanced Diagnosis And Treatment Solutions • Market Trend: AI-Powered Risk Assessment Enhances Prostate Cancer Diagnosis And Reduces Unnecessary Biopsies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Prostate Health Market?

Prostate health refers to the overall well-being and proper functioning of the prostate gland, a small organ in men that produces seminal fluid. Maintaining prostate health is essential for urinary function, reproductive health, and preventing conditions such as prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer. Factors influencing prostate health include age, genetics, diet, lifestyle, and regular medical screenings. The main disease indication in prostate health are prostate cancer, benign prostate hyperplasia, and prostatitis. Prostate cancer is a form of cancer that begins in the prostate gland, marked by the uncontrolled proliferation of prostate cells that may result in tumor formation and possible metastasis to other areas of the body. The different treatment include hormonal therapy, chemotherapy, surgical treatments, and others and various distribution channels are e-commerce stores, pharmacies, and others.

What Is The Prostate Health Market Growth Forecast?

The prostate health market size is expected to see strong growth in the next few years. It will grow to $57.39 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to growing adoption of personalized prostate care plans, rising use of digital health platforms, expansion of preventive healthcare programs, increasing demand for minimally invasive therapies, greater emphasis on long-term prostate wellness. Major trends in the forecast period include increasing focus on preventive prostate healthcare, rising adoption of non-invasive treatment options, growing demand for lifestyle and nutritional interventions, expansion of digital health monitoring solutions, enhanced emphasis on early screening and awareness.

What Is The Driver Of The Prostate Health Market?

The rising prevalence of prostate cancer is expected to propel the growth of the prostate health market going forward. Prostate cancer is a type of cancer that occurs when cells in the prostate gland grow uncontrollably, often manifesting as adenocarcinomas, which are the most common form of this disease in men. The rising prevalence of prostate cancer is primarily due to the growing aging population, increased screening practices, and lifestyle factors such as obesity and physical inactivity. Prostate health is essential for the prevention, early detection, and management of prostate cancer. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based, non-profit organization, in 2023, approximately 288,300 new prostate cancer cases were expected to be diagnosed in the U.S., with an estimated 34,700 fatalities resulting from the disease. Therefore, the rising prevalence of prostate cancer will drive the growth of the prostate health industry.

Key Players In The Global Prostate Health Market

Major companies operating in the prostate health market are Pfizer Inc, Johnson And Johnson, Bayer AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Co Ltd, Astellas Pharma Inc, Genentech Inc, Teleflex Inc, Elekta AB, Myriad Genetics Inc, Freenome, Theragenics Corporation, Roivant Sciences, Artera Inc, Veru Inc, HistoSonics Inc, Immunic Inc, Ezra, Francis Medical, Lucida Medical, Serimmune Inc, Alessa Therapeutics

Global Prostate Health Market Trends and Insights

Major companies operating in the prostate health market are focusing on technological advancements such as AI-powered risk assessment to gain a competitive edge. AI-powered risk assessment uses artificial intelligence algorithms to analyze data and predict potential risks, helping to make informed decisions and improve outcomes. For instance, in September 2024, Nanostics Inc., a Canada-based clinical-stage biotechnology company, and Protean BioDiagnostics, a US-based biotechnology company, partnered to launch CDX Prostate, a diagnostic tool aimed at men at risk of aggressive prostate cancer. This diagnostic tool utilizes biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer. CDX Prostate employs advanced machine learning algorithms to analyze various biological and clinical data, providing a more accurate risk score for aggressive prostate cancer compared to traditional methods. The test helps healthcare providers and patients make informed decisions about whether to proceed with a biopsy after a high prostate-specific antigen (PSA) test result or an abnormal digital rectal exam (DRE).

What Are Latest Mergers And Acquisitions In The Prostate Health Market?

In June 2024, Lantheus Holdings Inc., a US-based, radiopharmaceutical-focused company, acquired worldwide rights to Life Molecular Imaging's RM2, which targets the gastrin-releasing peptide receptor (GRPR) for an undisclosed amount. The aim of the acquisition is to strengthen Lantheus' presence in prostate cancer treatment and expand its pipeline to include breast and other cancers through the global rights to a novel radiotheranostic pair, including 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 targeting the gastrin-releasing peptide receptor (GRPR). Life Molecular Imaging is a Germany-based radiopharmaceutical company focused on creating and providing innovative radiopharmaceuticals that enhance the early detection and diagnosis of chronic and life-threatening conditions.

What Defines the Prostate Health Market?

The prostate health market includes revenues earned by entities providing services such as diagnostic screening, medical consultations, prostate cancer treatments, minimally invasive procedures for benign prostatic hyperplasia (BPH), telemedicine consultations, and wellness programs focused on prostate health. Only goods and services traded between entities or sold to end consumers are included. The prostate health market consists of sales of pharmaceuticals, medical devices, dietary supplements, and diagnostic kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Prostate Health Market Report 2026?

The prostate health market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prostate health industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.